Although most digital health solutions promise to impact chronic care positively, they fall short owing to data scarcity and frequent difficulties around integrating them into existing care workflows. Also, the entire chronic care health ecosystem— entailing health plans, health systems, and employers—need efficient means to reach people in a scalable manner, and become part of a robust population health management program. This is where Welldoc positions itself as an entity that delivers on the promise of digital health.
“Our advanced AI-driven insights help facilitate sustained behaviour change, and our comprehensive chronic care platform seamlessly integrates with existing clinical workflows to enable connected care, everywhere,” says Kevin McRaith, the president and CEO of Welldoc.
By integrating personalized, real-time, and actionable insights into the daily lives of individuals living with chronic conditions, Welldoc enables them to self-manage their care while enhancing connections to their healthcare team. The company collaborates directly with health plans, health systems, and employers with the goal of extending care, improving health, and reducing costs.
At its core, Welldoc's comprehensive chronic care platform provides multi-condition support across diabetes, pre-diabetes, hypertension, heart failure, and behavioral health. Additionally, Welldoc's advanced AI connects and leverages the member's health data across the six dimensions of health—medications, labs, diet, activity, symptoms, and psychosocial factors—to seek meaningful correlations to materialize real-time digital coaching personalized insights and care team support.
Welldoc’s flagship product is BlueStar®, an FDA-cleared digital health solution that guides individuals through the complicated journey of living with chronic conditions by enabling them to self-manage their care while enhancing connections to their healthcare team. The company’s platform is backed by a wealth of evidence and regulatory expertise. Its chronic care platform brings first-in-class clinical, tech, and advanced AI expertise, as demonstrated by Welldoc’s 60+ clinical posters and publications, 25 patents, and 9 510(k) FDA clearances for BlueStar. Specific to its diabetes offering, Welldoc demonstrated an average cost savings of $3,048-$3,252/person with Type 2 diabetes annually and a 1.2-2.0 point mean A1C reduction in individuals living with Type 2 diabetes. The company’s advanced AI is the critical engine behind the analytics, insights, and shared decision-making between patients and care teams.
Welldoc believes that partnership is the pathway to better management of chronic conditions and collaborates directly with health plans, health systems, and employers with the goal of extending care, improving health, and reducing costs.
“Our advanced AI-driven insights help facilitate sustained behaviour change, and our comprehensive chronic care platform seamlessly integrates with existing clinical workflows to enable connected care, everywhere,” says Kevin McRaith, the president and CEO of Welldoc.
By integrating personalized, real-time, and actionable insights into the daily lives of individuals living with chronic conditions, Welldoc enables them to self-manage their care while enhancing connections to their healthcare team. The company collaborates directly with health plans, health systems, and employers with the goal of extending care, improving health, and reducing costs.
At its core, Welldoc's comprehensive chronic care platform provides multi-condition support across diabetes, pre-diabetes, hypertension, heart failure, and behavioral health. Additionally, Welldoc's advanced AI connects and leverages the member's health data across the six dimensions of health—medications, labs, diet, activity, symptoms, and psychosocial factors—to seek meaningful correlations to materialize real-time digital coaching personalized insights and care team support.
Welldoc’s flagship product is BlueStar®, an FDA-cleared digital health solution that guides individuals through the complicated journey of living with chronic conditions by enabling them to self-manage their care while enhancing connections to their healthcare team. The company’s platform is backed by a wealth of evidence and regulatory expertise. Its chronic care platform brings first-in-class clinical, tech, and advanced AI expertise, as demonstrated by Welldoc’s 60+ clinical posters and publications, 25 patents, and 9 510(k) FDA clearances for BlueStar. Specific to its diabetes offering, Welldoc demonstrated an average cost savings of $3,048-$3,252/person with Type 2 diabetes annually and a 1.2-2.0 point mean A1C reduction in individuals living with Type 2 diabetes. The company’s advanced AI is the critical engine behind the analytics, insights, and shared decision-making between patients and care teams.
Welldoc believes that partnership is the pathway to better management of chronic conditions and collaborates directly with health plans, health systems, and employers with the goal of extending care, improving health, and reducing costs.
“Our deep relationships with life science industry leaders, health plans and health systems coupled with our advanced AI insights allows us to continually be improving our platform based on emerging needs of users and the overall healthcare ecosystem,” mentions McRaith.
Having carved a unique niche, Welldoc has adopted a multifaceted approach to continuing to evolve and lead in digital health. Over the course of the next three years, the company plans to expand commercialization beyond the US and Canada into both Asia and Europe. Further, Welldoc will continue to evolve the platform and integrate it to facilitate care for new chronic conditions and comorbidities based on the needs of individuals and the entirety of their user population. In collaboration with its strategic partners, the company will continue expanding regulatory clearances while extending capabilities to support and manage complex chronic conditions.
Additionally, Welldoc remains committed to its scientific research and growing library publications and posters, which will continue proving the value of digital health, transforming approaches to chronic care, and driving value across healthcare. The company will also further advance its research efforts in multi-conditional digital health engagement, AI, cardiometabolic condition outcomes, cost and value, and real-world integration into the health ecosystem. "As we expand partnerships, we provide meaningful and actionable coaching and insights to individuals and the care teams who support them, while also shifting healthcare to prevention and optimized interventions and treatment decisions," concludes McRaith.
Sources Cited: 1 IBM Watson Health. Estimating the economic value of a digital therapeutic in type 2 diabetes. Welldoc-sponsored report 2018. Published August 2018. 2 Tang PY, Duni J, Peeples MM, et al. Complementarity of digital health and peer support: “This Is What’s Coming.” Front Clin Diabetes Health. 2021;2. doi:10.3389/fcdhc.2021.646963 3 Quinn CC, Sareh PL, Shardell ML, Terrin ML, Barr EA, Gruber-Baldini AL. Mobile Diabetes Intervention for Glycemic Control. Journal of Diabetes Science and Technology. 2014;8(2):362-370. doi:10.1177/1932296813514503
Having carved a unique niche, Welldoc has adopted a multifaceted approach to continuing to evolve and lead in digital health. Over the course of the next three years, the company plans to expand commercialization beyond the US and Canada into both Asia and Europe. Further, Welldoc will continue to evolve the platform and integrate it to facilitate care for new chronic conditions and comorbidities based on the needs of individuals and the entirety of their user population. In collaboration with its strategic partners, the company will continue expanding regulatory clearances while extending capabilities to support and manage complex chronic conditions.
Our advanced AI-driven insights help facilitate sustained behavior change, and our comprehensive chronic care platform seamlessly integrates with existing clinical workflows to enable connected care, everywhere
Additionally, Welldoc remains committed to its scientific research and growing library publications and posters, which will continue proving the value of digital health, transforming approaches to chronic care, and driving value across healthcare. The company will also further advance its research efforts in multi-conditional digital health engagement, AI, cardiometabolic condition outcomes, cost and value, and real-world integration into the health ecosystem. "As we expand partnerships, we provide meaningful and actionable coaching and insights to individuals and the care teams who support them, while also shifting healthcare to prevention and optimized interventions and treatment decisions," concludes McRaith.
Sources Cited: 1 IBM Watson Health. Estimating the economic value of a digital therapeutic in type 2 diabetes. Welldoc-sponsored report 2018. Published August 2018. 2 Tang PY, Duni J, Peeples MM, et al. Complementarity of digital health and peer support: “This Is What’s Coming.” Front Clin Diabetes Health. 2021;2. doi:10.3389/fcdhc.2021.646963 3 Quinn CC, Sareh PL, Shardell ML, Terrin ML, Barr EA, Gruber-Baldini AL. Mobile Diabetes Intervention for Glycemic Control. Journal of Diabetes Science and Technology. 2014;8(2):362-370. doi:10.1177/1932296813514503
Company
Welldoc
Headquarters
Columbia, MD
Management
Kevin McRaith, President and CEO
Description
Welldoc’s comprehensive chronic care platform provides multi-condition support across diabetes, pre-diabetes, hypertension, heart failure, and behavioral health. Welldoc’s flagship product is BlueStar®, an FDA-cleared digital health solution that guides individuals through the complicated journey of living with chronic conditions by enabling them to self-manage their care while enhancing connections to their healthcare team. The company’s platform is backed by a wealth of evidence and regulatory expertise. Its chronic care platform brings first-in-class clinical, tech, and advanced AI expertise, as demonstrated by Welldoc’s 60+ clinical posters and publications, 25 patents, and 9 510(k) FDA clearances for BlueStar.
